WAI YUEN TONG MEDICINE HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.23 HKD | 0.00% |
|
-5.35% | -42.50% |
| Sales 2022 | 1.39B 178M 14.23B | Sales 2023 | 1.29B 164M 13.16B | Capitalization | 434M 55.4M 4.44B |
|---|---|---|---|---|---|
| Net income 2022 | -109M -13.92M -1.11B | Net income 2023 | -20M -2.55M -205M | EV / Sales 2022 | 1.1 x |
| Net Debt 2022 | 1.17B 150M 12.01B | Net Debt 2023 | 1.2B 153M 12.23B | EV / Sales 2023 | 1.27 x |
| P/E ratio 2022 |
-3.28
x | P/E ratio 2023 |
-21.3
x | Employees | 1,962 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.81% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -5.35% | ||
| Current month | -5.74% | ||
| 1 month | -7.63% | ||
| 3 months | -47.13% | ||
| 6 months | -41.03% | ||
| Current year | -42.50% |
1 week
0.22
0.24
1 month
0.210.27
Current year
0.100.46
1 year
0.100.46
3 years
0.100.51
5 years
0.100.51
10 years
0.106.10
| Managers | Title | Age | Since |
|---|---|---|---|
Ching Ho Tang
CEO | Chief Executive Officer | 62 | 27/08/01 |
Yuen Wo Tsang
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/18 |
Seung Ming Wong
AUD | Comptroller/Controller/Auditor | 52 | 31/01/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ka Fai Li
BRD | Director/Board Member | 69 | 16/03/15 |
Ching Ho Tang
CEO | Chief Executive Officer | 62 | 27/08/01 |
Man Ho Siu
BRD | Director/Board Member | 50 | 31/07/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.23 | 0.00% | 170,000 |
| 25/04/24 | 0.23 | 0.00% | 40,000 |
| 24/04/24 | 0.23 | +1.77% | 142,500 |
| 23/04/24 | 0.226 | -3.83% | 185,288 |
| 22/04/24 | 0.235 | -3.29% | 145,156 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Wai Yuen Tong Medicine Holdings Limited is a Hong Kong-based investment holding company principally engaged in the production and sales of pharmaceutical products. The Company operates through three segments. Production and Sale of Chinese Pharmaceutical and Health Food Products segment is mainly engaged in the manufacture, processing and retailing of traditional Chinese medicine in China and Hong Kong. Its products include Chinese medicines under the brand Wai Yuen Tong, as well as products manufactured with traditional prescriptions. Production and Sale of Western Pharmaceutical and Health Food Products segment is engaged in the processing and sales of Western pharmaceutical products and personal care products under the brands Madame Pearlâs and Pearlâs. Property Investment segment is engaged in the investment in commercial properties for rental income.
Sector
Pharmaceuticals
Calendar
24/06/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -42.50% | 33.06M | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- 897 Stock
